Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2012 3
2013 3
2014 10
2015 9
2016 11
2017 10
2018 6
2019 14
2020 18
2021 20
2022 10
2023 3
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

108 results

Results by year

Filters applied: . Clear all
Page 1
Perioperative Nivolumab in Resectable Lung Cancer.
Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, Tanaka F, Taube JM, Cornelissen R, Havel L, Karaseva N, Kuzdzal J, Petruzelka LB, Wu L, Pujol JL, Ito H, Ciuleanu TE, de Oliveira Muniz Koch L, Janssens A, Alexandru A, Bohnet S, Moiseyenko FV, Gao Y, Watanabe Y, Coronado Erdmann C, Sathyanarayana P, Meadows-Shropshire S, Blum SI, Provencio Pulla M; CheckMate 77T Investigators. Cascone T, et al. N Engl J Med. 2024 May 16;390(19):1756-1769. doi: 10.1056/NEJMoa2311926. N Engl J Med. 2024. PMID: 38749033 Clinical Trial.
Improved overall survival in patients developing endocrine toxicity during treatment with nivolumab for advanced non-small cell lung cancer in a prospective study.
Albertelli M, Rossi G, Nazzari E, Genova C, Biello F, Rijavec E, Dal Bello MG, Patti L, Tagliamento M, Barletta G, Morabito P, Boschetti M, Dotto A, Campana D, Ferone D, Grossi F. Albertelli M, et al. Among authors: rijavec e. J Endocrinol Invest. 2024 Apr 29. doi: 10.1007/s40618-023-02268-0. Online ahead of print. J Endocrinol Invest. 2024. PMID: 38683497
Management of patients with extensive small-cell lung cancer in the immunotherapy era: an Italian consensus through a Delphi approach.
Ceresoli GL, Rossi G, Agustoni F, Bonomi L, Borghetti P, Bulotta A, Casartelli C, Cerea G, Colonese F, Del Signore E, Finocchiaro G, Gianoncelli L, Grisanti S, Maiolani M, Pagni F, Proto C, Rijavec E, Vittimberga I, Arcangeli S, Filippi AR. Ceresoli GL, et al. Among authors: rijavec e. Crit Rev Oncol Hematol. 2024 Jan 31:104247. doi: 10.1016/j.critrevonc.2023.104247. Online ahead of print. Crit Rev Oncol Hematol. 2024. PMID: 38307393 Review.
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study.
Cantini L, Paoloni F, Pecci F, Spagnolo F, Genova C, Tanda ET, Aerts S, Rebuzzi SE, Fornarini G, Zoratto F, Fancelli S, Lupi A, Della Corte CM, Parisi A, Bennati C, Ortega C, Atzori F, Piovano PL, Orciuolo C, De Tursi M, Ghidini M, Botticelli A, Scagnoli S, Belluomini L, Leporati R, Veccia A, Di Giacomo AM, Festino L, Cortinovis D, Acquati M, Filetti M, Giusti R, Tucci M, Sergi MC, Garutti M, Puglisi F, Manglaviti S, Citarella F, Santoni M, Rijavec E, Lo Russo G, Santini D, Addeo A, Antonuzzo L, Indini A, Rocchi MBL, Cortellini A, Grossi F, Ascierto PA, Aerts JGJV, Berardi R. Cantini L, et al. Among authors: rijavec e. J Natl Cancer Inst. 2023 Jul 6;115(7):796-804. doi: 10.1093/jnci/djad061. J Natl Cancer Inst. 2023. PMID: 37042716 Free PMC article.
Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
Genova C, Tasso R, Rosa A, Rossi G, Reverberi D, Fontana V, Marconi S, Croce M, Dal Bello MG, Dellepiane C, Tagliamento M, Ciferri MC, Zullo L, Fedeli A, Alama A, Cortese K, Gentili C, Cella E, Anselmi G, Mora M, Barletta G, Rijavec E, Grossi F, Pronzato P, Coco S. Genova C, et al. Among authors: rijavec e. Cells. 2023 Mar 8;12(6):832. doi: 10.3390/cells12060832. Cells. 2023. PMID: 36980174 Free PMC article.
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817.
Ready NE, Audigier-Valette C, Goldman JW, Felip E, Ciuleanu TE, Rosario García Campelo M, Jao K, Barlesi F, Bordenave S, Rijavec E, Urban L, Aucoin JS, Zannori C, Vermaelen K, Arén Frontera O, Curioni Fontecedro A, Sánchez-Gastaldo A, Juan-Vidal O, Linardou H, Poddubskaya E, Spigel DR, Ahmed S, Maio M, Li S, Chang H, Fiore J, Acevedo A, Paz-Ares L. Ready NE, et al. Among authors: rijavec e. J Immunother Cancer. 2023 Feb;11(2):e006127. doi: 10.1136/jitc-2022-006127. J Immunother Cancer. 2023. PMID: 36725084 Free PMC article. Clinical Trial.
Immune checkpoint inhibitor therapy for hepatocellular carcinoma.
Ramai D, Shapiro A, Facciorusso A, Bareggi C, Gambini D, Rijavec E, Tomasello G, Galassi B, Ghidini M. Ramai D, et al. Among authors: rijavec e. Ann Gastroenterol. 2022 Nov-Dec;35(6):568-576. doi: 10.20524/aog.2022.0746. Epub 2022 Oct 3. Ann Gastroenterol. 2022. PMID: 36406972 Free PMC article. Review.
Renal Function Outcomes in Metastatic Non-Small-Cell Lung Carcinoma Patients Treated with Chemotherapy or Immune Checkpoint Inhibitors: An Unexpected Scenario.
Trevisani F, Di Marco F, Floris M, Pani A, Minnei R, Scartozzi M, Cirillo A, Gelibter A, Botticelli A, Rijavec E, Cattaneo M, Garrone O, Ghidini M. Trevisani F, et al. Among authors: rijavec e. Vaccines (Basel). 2022 Apr 24;10(5):679. doi: 10.3390/vaccines10050679. Vaccines (Basel). 2022. PMID: 35632435 Free PMC article.
108 results